目的 探討膽益寧片聯(lián)合曲匹布通治療慢性膽囊炎的臨床療效。方法 選取2020年2月—2021年2月在咸陽市第一人民醫(yī)院診治的114例慢性膽囊炎患者，依據(jù)用藥的差距分為對照組和治療組，每組各57例。對照組口服曲匹布通片，40 mg/次，3次/d；治療組在對照組基礎(chǔ)上口服膽益寧片，0.6 g/次，3次/d。兩組患者均治療2周。觀察兩組患者臨床療效，比較治療前后兩組患者臨床癥狀緩解時間、膽囊壁厚度、膽囊容積、膽囊收縮功能及血清C反應(yīng)蛋白（CRP）、白細(xì)胞介素6（IL-6）、瘦素（LEP）、核因子κB（NF-κB）和IL-13水平。結(jié)果 經(jīng)治療，治療組總有效率顯著優(yōu)于對照組（98.25%vs 82.46%，P<0.05）。經(jīng)治療，治療組癥狀緩解時間明顯早于對照組（P<0.05）。經(jīng)治療，兩組患者膽囊壁厚度、膽囊容積明顯下降，而膽囊收縮功能明顯升高（P<0.05），且治療組改善最顯著（P<0.05）。經(jīng)治療，兩組患者血清CRP、IL-6、LEP、NF-κB水平明顯下降，而IL-13明顯升高（P<0.05），且治療組明顯好于對照組（P<0.05）。結(jié)論 膽益寧片聯(lián)合曲匹布通片治療慢性膽囊炎可有效改善患者臨床癥狀，降低機體炎癥因子水平，提高患者膽囊功能，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical effect of Danyining Tablets combined with trapibutong in treatment of chronic cholecystitis. Methods Patients (114 cases) with chronic cholecystitis in the First People's Hospital of Xianyang from February 2020 to February 2021 were divided into control and treatment groups based on different treatments, and each group had 57 cases. Patients in the control group were po administered with Trepibutone Tablets, 40 mg/time, three times daily. Patients in the treatment group were po administered with Danyining Tablets, 0.6 g/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, the remission time of clinical symptoms, gallbladder wall thickness, gallbladder volume and gallbladder systolic function, and the levels of serum CRP, IL-6, LEP, NF-κB, and IL-13 in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was significantly better than that of the control group (98.25% vs 82.46%, P < 0.05). After treatment, the time of symptom relief in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, the gallbladder wall thickness and gallbladder volume in two groups were significantly decreased, while the gallbladder contractile function were significantly improved (P < 0.05), and the treatment group improved most significantly (P < 0.05). After treatment, the levels of serum CRP, IL-6, LEP, and NF-κB in two groups were significantly decreased, while IL-13 was significantly increased (P < 0.05), and the treatment group was significantly better than the control group (P < 0.05). Conclusion Danyining Tablets combined with trapibutong in treatment of chronic cholecystitis can effectively improve the clinical symptoms, reduce the level of inflammatory factors and improve the gallbladder function of patients, which has a certain clinical application value.

R975